Evaluation of Specific Cellular and Humoral Immune Response to Toxoplasma gondii in Patients with Autoimmune Rheumatic Diseases Immunomodulated Due to the Use of TNF Blockers

(1) Background: TNF antagonists have been used to treat autoimmune diseases (AD). However, during the chronic phase of toxoplasmosis, TNF-α and TNFR play a significant role in maintaining disease resistance and latency. Several studies have demonstrated the risk of latent infections’ reactivation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrade, Cristhianne Molinero Ratkevicius, de Lima Marques, Aline Caroline, Timóteo, Rodolfo Pessato, de Morais Oliveira-Scussel, Ana Carolina, De Vito, Fernanda Bernadelli, da Silva, Marcos Vinícius, Mineo, José Roberto, Teodoro, Reginaldo Botelho, Rodrigues, Denise Bertulucci Rocha, Júnior, Virmondes Rodrigues
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046324/
https://www.ncbi.nlm.nih.gov/pubmed/36979909
http://dx.doi.org/10.3390/biomedicines11030930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046324/
https://www.ncbi.nlm.nih.gov/pubmed/36979909
http://dx.doi.org/10.3390/biomedicines11030930

Ejemplares similares